MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research.
|Title||MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research.|
|Publication Type||Journal Article|
|Year of Publication||2014|
|Authors||Zimmer ER, Parent MJ, A Cuello C, Gauthier S, Rosa-Neto P|
|Date Published||2014 Nov|
|Keywords||Alzheimer Disease, Amyloid beta-Peptides, Animals, Brain, Disease Models, Animal, Humans, Neuroimaging, Positron-Emission Tomography|
Over the past decades, developments in neuroimaging have significantly contributed to the understanding of Alzheimer's disease (AD) pathophysiology. Specifically, positron emission tomography (PET) imaging agents targeting amyloid deposition have provided unprecedented opportunities for refining in vivo diagnosis, monitoring disease propagation, and advancing AD clinical trials. Furthermore, the use of a miniaturized version of PET (microPET) in transgenic (Tg) animals has been a successful strategy for accelerating the development of novel radiopharmaceuticals. However, advanced applications of microPET focusing on the longitudinal propagation of AD pathophysiology or therapeutic strategies remain in their infancy. This review highlights what we have learned from microPET imaging in Tg models displaying amyloid and tau pathology, and anticipates cutting-edge applications with high translational value to clinical research.
|Alternate Journal||Trends Neurosci.|
|Grant List||MOP 10-27-52 / / Canadian Institutes of Health Research / Canada |
MOP-11-51-31 / / Canadian Institutes of Health Research / Canada